NKGen Biotech, Inc. (NKGN)
NKGN moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How NKGN actually reacts to news — the realized, point-in-time move the market made, measured across 132 labeled events over the last three years with zero look-ahead.
NKGN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 26% | 116 |
| 30-min | 0.00% | 37% | 123 |
| 60-min | 0.00% | 36% | 124 |
| to close | 0.00% | 34% | 124 |
| Middle 50% of NKGN reactions | -2.80% to +2.67% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 132 |
Half of all NKGen Biotech, Inc. news events land between -2.80% and +2.67% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NKGN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NKGN's baseline. Nothing else.
Recent NKGN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026 | Press release | GlobeNewswire | — | — | |
| Form 8-K NKGen Biotech, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K NKGen Biotech, Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K NKGen Biotech, Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K NKGen Biotech, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment | Press release | GlobeNewswire | — | — | |
| Form 8-K NKGen Biotech, Inc. For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K NKGen Biotech, Inc. For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™ | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026 | Press release | GlobeNewswire | — | — | |
| Form 8-K NKGen Biotech, Inc. For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K NKGen Biotech, Inc. For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K NKGen Biotech, Inc. For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -52.90% | |
| NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 10-Q NKGen Biotech, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K NKGen Biotech, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K NKGen Biotech, Inc. For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd. | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 10-K NKGen Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.00% | |
| NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K NKGen Biotech, Inc. For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K NKGen Biotech, Inc. For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum | Press release | GlobeNewswire | +0.00% | +4.15% | |
| Form 8-K NKGen Biotech, Inc. For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit | Press release | GlobeNewswire | — | — | |
| NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025 | Press release | GlobeNewswire | +0.00% | +0.00% | |
| NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025 | Press release | GlobeNewswire | -2.33% | -2.33% | |
| NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases | Press release | GlobeNewswire | +0.00% | +12.94% | |
| Form 8-K NKGen Biotech, Inc. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +6.00% | -4.00% | |
| NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan | Press release | GlobeNewswire | +6.00% | -4.00% | |
| Form 8-K NKGen Biotech, Inc. For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -15.25% | |
| NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards | Press release | GlobeNewswire | +0.00% | -15.25% | |
| NKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy | Press release | GlobeNewswire | +0.00% | -3.19% | |
| NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer’s Trial with Activation of Clinical Sites in Canada and Florida | Press release | GlobeNewswire | -7.65% | -14.42% | |
| Form 8-K NKGen Biotech, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -0.39% | +3.71% | |
| Form 8-K NKGen Biotech, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +6.90% | -3.45% | |
| Form NT 10-Q NKGen Biotech, Inc. For: Mar 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | +6.81% | |
| Form 8-K NKGen Biotech, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +18.61% | |
| NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations | Press release | GlobeNewswire | +0.00% | +18.61% | |
| NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting | Press release | GlobeNewswire | +0.00% | +2.34% | |
| Form 8-K NKGen Biotech, Inc. For: Apr 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.72% | |
| Form 8-K NKGen Biotech, Inc. For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.80% | |
| NKGen Biotech To Present on the Use of Troculeucel for Alzheimer’s and Parkinson’s Disease at the 7th China International Biotechnology Conference & Exhibition | Press release | GlobeNewswire | -6.91% | -6.83% | |
| NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) | Press release | GlobeNewswire | +0.90% | -27.13% | |
| Form NT 10-K NKGen Biotech, Inc. For: Dec 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | -2.02% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NKGN section they belong to.
Where else NKGN is measured.
NKGN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NKGen Biotech, Inc.'s median reaction calculated?
Every labeled NKGN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 132 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of NKGN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NKGN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.